共 14 条
[1]
BAY43-9006inhibition of oncogenic RET mutants. CARLOMAGNO F,ANAGANTI S,GUIDAT,et al. Journal of the National Cancer Institute . 2006
[2]
Emerging role oftyrosine kinase inhibitors in the treatment of advanced renal cellcancer:a review. SCHOFFSKI P,DUMEZ H,CLEMENTP,et al. Annals of Oncology . 2006
[3]
Phase I study to determinethe safety and pharmacokinetics of the novel Raf kinase and VEG-FR inhibitor BAY 43-9006,administered for 28 days on/7 daysoff in patients with advanced,refractory solid tumors. MOORE M,HIRTE HW,SIUL,et al. Annals of Oncology . 2005
[4]
Syn-ergistic inhibition of human melanoma proliferation by combina-tion treatment with B-Raf inhibitor BAY43-9006 and mTOR in-hibitor Rapamycin. MOLHOEK KR,BRAUTIGAN DL,SLINGLUFF CL,Jr. JTransl Med . 2005
[5]
Sorafenib. RINI BI. Expert Opinion on Pharmacotherapy . 2006
[6]
Results of aphase I trial of Sorafenib(BAY43-9006)in combination with ox-aliplatin in patients with refractory solid tumors,including color-ectal cancer. KUPSCH P,HENNING BF,PASSARGE K,et al. Clinical Colorectal Cancer . 2005
[7]
Preclinical and clinical development of the oralmultikinase inhibitor Sorafenib in cancer treatment. STRUMBERG D. Drugs To-day(Barc) . 2005
[8]
Targeting intracellular signalingpathways as a novel strategy in melanoma therapeutics. SMALLEY KS,HERLYN M. Annals of the New York Academy of Sciences . 2005
[9]
The Raf inhibitorBAY43-9006(Sorafenib)induces caspase-independent apoptosisin melanoma cells. PANKA DJ,WANG W,ATKINS MB,et al. Cancer Research . 2006
[10]
Phase I clinicaland pharmacokinetic study of the Novel Raf kinase and vascularendothelial growth factor receptor inhibitor BAY 43-9006 in pa-tients with advanced refractory solid tumors. STRUMBERG D,RICHLYH,HILGER RA,et al. Journal of Clinical Oncology . 2005